Long‐term outcomes of patients with Crohn's disease who received infliximab or adalimumab as the first‐line biologics-Reference-Cited by-同舟云学术

Long‐term outcomes of patients with Crohn's disease who received infliximab or adalimumab as the first‐line biologics

Published:2019-02-06 Issue: Volume: Page:
ISSN:0815-9319
Container-title:Journal of Gastroenterology and Hepatology
language:en
Short-container-title:Journal of Gastroenterology and Hepatology

Author:

Inokuchi Toshihiro¹,Takahashi Sakuma²,Hiraoka Sakiko¹,Toyokawa Tatsuya³,Takagi Shinjiro⁴,Takemoto Koji⁵,Miyaike Jiro⁶,Fujimoto Tsuyoshi⁷,Higashi Reiji⁸,Morito Yuki⁹,Nawa Toru¹⁰,Suzuki Seiyuu¹¹,Nishimura Mamoru¹²,Inoue Masafumi¹³,Kato Jun¹⁴,Okada Hiroyuki¹

Affiliation:

1. Department of Gastroenterology and HepatologyOkayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan

2. Department of GastroenterologyKagawa Prefectural Central Hospital Kagawa Japan

3. Department of GastroenterologyNational Hospital Organization Fukuyama Medical Center Hiroshima Japan

4. Department of Internal MedicineJapanese Red Cross Society Himeji Hospital Hyogo Japan

5. Department of Internal MedicineTsuyama Central Hospital Okayama Japan

6. Department of GastroenterologySaiseikai Imabari General Hospital Ehime Japan

7. Department of GastroenterologyNational Hospital Organization Iwakuni Clinical Center Yamaguchi Japan

8. Department of EndoscopyHiroshima City Hiroshima Citizens Hospital Hiroshima Japan

9. Department of GastroenterologyMitoyo General Hospital Kagawa Japan

10. Department of GastroenterologyFukuyama City Hospital Hiroshima Japan

11. Department of Internal MedicineSumitomo Besshi Hospital Ehime Japan

12. Department of GastroenterologyOkayama City Hospital Okayama Japan

13. Department of GastroenterologyJapanese Red Cross Okayama Hospital Okayama Japan

14. Department of GastroenterologyMitsui Memorial Hospital Tokyo Japan

Publisher

Wiley

Subject

Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jgh.14624

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunomodulator combination versus mono therapy: Does combination therapy have an impact on infliximab therapy?;Digestive and Liver Disease;2023-12

2. The treatment of inflammatory bowel disease with monoclonal antibodies in Asia;Biomedicine & Pharmacotherapy;2023-01

3. Efficacy and safety of adalimumab in comparison to infliximab for Crohn's disease: A systematic review and meta-analysis;World Journal of Clinical Cases;2022-06-26

4. Adalimumab vs Infliximab in Pediatric Patients With Crohn's Disease: A Propensity Score Analysis and Predictors of Treatment Escalation;Clinical and Translational Gastroenterology;2022-04-01

5. Trends in the use of biologicals and their treatment outcomes among patients with inflammatory bowel diseases – a Danish nationwide cohort study;Alimentary Pharmacology & Therapeutics;2021-12-08